EpiCept
Corporation (NASDAQ:EPCT) skyrocketed 42.73% to $0.999 on unusual
volumes. The company reported results of a new analysis supporting Ceplene's
favorable impact on overall survival and its activity with interleukin-2 or
IL-2.
Ceplene
is approved in the European Union for the maintenance of first remission in
patients with Acute Myeloid Leukemia or AML in conjunction with low dose IL-2.
Previously,
EpiCept announced that it reached agreement with the U.S. Food and Drug
Administration or FDA for a two-arm, randomized, open-label trial that will
compare the efficacy of Ceplene plus low-dose IL-2 to standard practice in this
indication. Based on FDA guidance, the primary endpoint of the trial will be
overall patient survival.
Biodel
Inc (NASDAQ:BIOD) is down 8.89% to $1.64. The 52-week range of
the stock is $1.50-$6.25.
The
stock opened at $1.74 and is trading within the range of $1.61-$1.74. The stock
lost more than 62% year-to-date.
Inuvo,
Inc. (AMEX:INUV) is trading 13.07% higher at $0.540. The 52-week
range of the stock is $0.13-$0.55. The stock made its fresh one-year high of
$0.55.
The stock has average daily volume of 174K shares.
Article published by Wall Street Grand. Visit the Wall Street Grand Club today.
Disclaimer:
For our full disclosure please visit - http://www.wallstreetgrand.com/disclosure.html
